These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 22641810)

  • 21. Testing for human papillomavirus in cervical cancer screening: a review of indications and methodology.
    Nishino HT; Tambouret RH; Wilbur DC
    Cancer Cytopathol; 2011 Aug; 119(4):219-27. PubMed ID: 21717588
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Performance of visual inspection with acetic acid and human papillomavirus testing for detection of high-grade cervical lesions in HIV positive and HIV negative Tanzanian women.
    Dartell MA; Rasch V; Iftner T; Kahesa C; Mwaiselage JD; Junge J; Gernow A; Ejlersen SF; Munk C; Kjaer SK
    Int J Cancer; 2014 Aug; 135(4):896-904. PubMed ID: 24391021
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of HPV test versus conventional and automation-assisted Pap screening as potential screening tools for preventing cervical cancer.
    Nieminen P; Vuorma S; Viikki M; Hakama M; Anttila A
    BJOG; 2004 Aug; 111(8):842-8. PubMed ID: 15270934
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized controlled trial of human papillomavirus testing versus Pap cytology in the primary screening for cervical cancer precursors: design, methods and preliminary accrual results of the Canadian cervical cancer screening trial (CCCaST).
    Mayrand MH; Duarte-Franco E; Coutlée F; Rodrigues I; Walter SD; Ratnam S; Franco EL;
    Int J Cancer; 2006 Aug; 119(3):615-23. PubMed ID: 16572425
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rightsizing cervical cancer screening: comment on "Cervical cancer screening with both human papillomavirus and Papanicolaou testing vs Papanicolaou testing alone".
    Sawaya GF
    Arch Intern Med; 2010 Jun; 170(11):985-6. PubMed ID: 20548012
    [No Abstract]   [Full Text] [Related]  

  • 26. [HPV test makes cytological examination more accurate. Cervical cancer can be discovered more efficiently].
    Andersson S; Hjerpe A; Johansson BC; Hagmar B
    Lakartidningen; 2007 Sep 26-Oct 2; 104(39):2797-9. PubMed ID: 17958005
    [No Abstract]   [Full Text] [Related]  

  • 27. Self-collection of vaginal specimens for human papillomavirus testing in cervical cancer prevention (MARCH): a community-based randomised controlled trial.
    Lazcano-Ponce E; Lorincz AT; Cruz-Valdez A; Salmerón J; Uribe P; Velasco-Mondragón E; Nevarez PH; Acosta RD; Hernández-Avila M
    Lancet; 2011 Nov; 378(9806):1868-73. PubMed ID: 22051739
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Low prevalence of high-risk HPV in older women not attending organized cytological screening: a pilot study.
    Wikström I; Stenvall H; Wilander E
    Acta Derm Venereol; 2007; 87(6):554-5. PubMed ID: 17989903
    [No Abstract]   [Full Text] [Related]  

  • 29. Cervical cancer screening with both human papillomavirus and Papanicolaou testing vs Papanicolaou testing alone: what screening intervals are physicians recommending?
    Saraiya M; Berkowitz Z; Yabroff KR; Wideroff L; Kobrin S; Benard V
    Arch Intern Med; 2010 Jun; 170(11):977-85. PubMed ID: 20548011
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HPV testing. Visible expectations and hidden realities.
    Federschneider JM; Crum CP
    Am J Clin Pathol; 2003 Oct; 120(4):483-4. PubMed ID: 14560559
    [No Abstract]   [Full Text] [Related]  

  • 31. Patient safety and the next generation of HPV DNA tests.
    Lee SH
    Am J Clin Pathol; 2011 Mar; 135(3):481; author reply 482-3. PubMed ID: 21350106
    [No Abstract]   [Full Text] [Related]  

  • 32. Cervical cancer screening programs in low-income communities. Experiences from Ecuador. Low cost detection of HPV infection in a developing country.
    Cecchini G; Paganini G; D'Amico M; Cannone M; Bertuletti C; Barberis MC
    Pathologica; 2009 Apr; 101(2):76-9. PubMed ID: 19886552
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The latest recommendations from the USPSTF.
    Campos-Outcalt D
    J Fam Pract; 2012 May; 61(5):278-82. PubMed ID: 22577630
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cervical Cancer Screening: More Choices in 2019.
    Sawaya GF; Smith-McCune K; Kuppermann M
    JAMA; 2019 May; 321(20):2018-2019. PubMed ID: 31135834
    [No Abstract]   [Full Text] [Related]  

  • 35. Andrology and accreditation - An opportunity for Cytologists.
    Holland L; Maddox A
    Cytopathology; 2019 Nov; 30(6):650-652. PubMed ID: 31400165
    [No Abstract]   [Full Text] [Related]  

  • 36. New innovations in cervical cancer screening.
    Cohn DE; Herzog TJ
    Clin Obstet Gynecol; 2001 Sep; 44(3):538-49. PubMed ID: 11685878
    [No Abstract]   [Full Text] [Related]  

  • 37. Cervical cancer screening in Santiago Atitlán, Guatemala.
    Frey MK; Roselli N; Gertz E; Cuc JC; Boyd L; Shirazian T
    Int J Gynaecol Obstet; 2016 Oct; 135(1):119. PubMed ID: 27451397
    [No Abstract]   [Full Text] [Related]  

  • 38. [Assessment of human papilloma virus (HPV) testing in primary screening for cervical cancer in France (May 2004)].
    ANAES
    Gynecol Obstet Fertil; 2005 May; 33(5):357-60. PubMed ID: 15999430
    [No Abstract]   [Full Text] [Related]  

  • 39. A nurse-led cervical screening clinic in primary care.
    Young G
    Rev Infirm; 2018 Feb; 67(238):47-48. PubMed ID: 29426562
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Avoiding inappropriate invitations to cancer screening programmes: the role of primary care.
    Campbell C; Anandan C; Appleton S; Elton R; Patnick J; Weller D
    J Med Screen; 2011; 18(1):12-7. PubMed ID: 21536811
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.